Avacta Group Plc
Avacta Group Plc (AVCT.L) Stock Competitors & Peer Comparison
See (AVCT.L) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AVCT.L | £47.00 | -8.74% | 188.7M | -5.22 | -£0.09 | N/A |
| 0QW0.L | £352.20 | -1.36% | 13.4B | -31.93 | -£11.03 | N/A |
| 0A8K.L | £31.24 | +0.03% | 8.3B | -53.04 | -£0.59 | N/A |
| 0H22.L | £44.54 | +0.00% | 2.7B | -9.78 | -£4.56 | N/A |
| 0RC7.L | £84.70 | -18.94% | 2.3B | N/A | N/A | N/A |
| 0HI3.L | £15.70 | -3.39% | 2.2B | -14.87 | -£1.08 | N/A |
| ONT.L | £199.50 | -2.21% | 1.9B | -12.47 | -£0.16 | N/A |
| GNS.L | £2,490.00 | -0.20% | 1.6B | -415.00 | -£0.06 | +1.29% |
| 0RC6.L | £73.87 | +0.00% | 1.5B | 14.69 | £5.03 | +1.01% |
| 0K1R.L | £17.29 | -1.48% | 1.4B | -3.37 | -£5.14 | N/A |
Stock Comparison
AVCT.L vs 0QW0.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0QW0.L has a market cap of 13.4B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0QW0.L trades at £352.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0QW0.L's P/E ratio is -31.93. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0QW0.L's ROE of +0.17%. Regarding short-term risk, AVCT.L is more volatile compared to 0QW0.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0QW0.L's competition here
AVCT.L vs 0A8K.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0A8K.L has a market cap of 8.3B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0A8K.L trades at £31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0A8K.L's P/E ratio is -53.04. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0A8K.L's ROE of -1.43%. Regarding short-term risk, AVCT.L is more volatile compared to 0A8K.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0A8K.L's competition here
AVCT.L vs 0H22.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0H22.L has a market cap of 2.7B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0H22.L trades at £44.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0H22.L's P/E ratio is -9.78. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0H22.L's ROE of -0.50%. Regarding short-term risk, AVCT.L is more volatile compared to 0H22.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0H22.L's competition here
AVCT.L vs 0RC7.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0RC7.L has a market cap of 2.3B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0RC7.L trades at £84.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0RC7.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0RC7.L's ROE of +1.43%. Regarding short-term risk, AVCT.L is more volatile compared to 0RC7.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0RC7.L's competition here
AVCT.L vs 0HI3.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0HI3.L has a market cap of 2.2B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0HI3.L trades at £15.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0HI3.L's P/E ratio is -14.87. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0HI3.L's ROE of -0.46%. Regarding short-term risk, AVCT.L is more volatile compared to 0HI3.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0HI3.L's competition here
AVCT.L vs ONT.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ONT.L has a market cap of 1.9B. Regarding current trading prices, AVCT.L is priced at £47.00, while ONT.L trades at £199.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ONT.L's P/E ratio is -12.47. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ONT.L's ROE of -0.25%. Regarding short-term risk, AVCT.L is more volatile compared to ONT.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check ONT.L's competition here
AVCT.L vs GNS.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, GNS.L has a market cap of 1.6B. Regarding current trading prices, AVCT.L is priced at £47.00, while GNS.L trades at £2,490.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas GNS.L's P/E ratio is -415.00. In terms of profitability, AVCT.L's ROE is -0.90%, compared to GNS.L's ROE of -0.01%. Regarding short-term risk, AVCT.L is more volatile compared to GNS.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check GNS.L's competition here
AVCT.L vs 0RC6.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0RC6.L has a market cap of 1.5B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0RC6.L trades at £73.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0RC6.L's P/E ratio is 14.69. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0RC6.L's ROE of +0.10%. Regarding short-term risk, AVCT.L is less volatile compared to 0RC6.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check 0RC6.L's competition here
AVCT.L vs 0K1R.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0K1R.L has a market cap of 1.4B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0K1R.L trades at £17.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0K1R.L's P/E ratio is -3.37. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0K1R.L's ROE of -0.49%. Regarding short-term risk, AVCT.L is more volatile compared to 0K1R.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0K1R.L's competition here
AVCT.L vs 0RHR.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0RHR.L has a market cap of 1.1B. Regarding current trading prices, AVCT.L is priced at £47.00, while 0RHR.L trades at £30.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0RHR.L's P/E ratio is -131.83. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0RHR.L's ROE of -0.07%. Regarding short-term risk, AVCT.L is more volatile compared to 0RHR.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0RHR.L's competition here
AVCT.L vs 0A8E.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0A8E.L has a market cap of 825M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0A8E.L trades at £5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0A8E.L's P/E ratio is -3.64. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0A8E.L's ROE of +1.60%. Regarding short-term risk, AVCT.L is more volatile compared to 0A8E.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0A8E.L's competition here
AVCT.L vs ERGO.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ERGO.L has a market cap of 771.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while ERGO.L trades at £1,348.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ERGO.L's P/E ratio is 48.14. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ERGO.L's ROE of +0.20%. Regarding short-term risk, AVCT.L is more volatile compared to ERGO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check ERGO.L's competition here
AVCT.L vs 0AAJ.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0AAJ.L has a market cap of 744.1M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0AAJ.L trades at £22.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0AAJ.L's P/E ratio is 15.07. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0AAJ.L's ROE of -0.05%. Regarding short-term risk, AVCT.L is more volatile compared to 0AAJ.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0AAJ.L's competition here
AVCT.L vs 0RQE.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0RQE.L has a market cap of 588.9M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0RQE.L trades at £11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0RQE.L's P/E ratio is -2.68. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0RQE.L's ROE of +0.20%. Regarding short-term risk, AVCT.L is more volatile compared to 0RQE.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0RQE.L's competition here
AVCT.L vs OXB.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, OXB.L has a market cap of 493M. Regarding current trading prices, AVCT.L is priced at £47.00, while OXB.L trades at £464.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas OXB.L's P/E ratio is -11.06. In terms of profitability, AVCT.L's ROE is -0.90%, compared to OXB.L's ROE of -0.70%. Regarding short-term risk, AVCT.L is more volatile compared to OXB.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check OXB.L's competition here
AVCT.L vs PRTC.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, PRTC.L has a market cap of 331.6M. Regarding current trading prices, AVCT.L is priced at £47.00, while PRTC.L trades at £138.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas PRTC.L's P/E ratio is 8.63. In terms of profitability, AVCT.L's ROE is -0.90%, compared to PRTC.L's ROE of +0.15%. Regarding short-term risk, AVCT.L is more volatile compared to PRTC.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check PRTC.L's competition here
AVCT.L vs 0I0X.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0I0X.L has a market cap of 222.1M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0I0X.L trades at £2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0I0X.L's P/E ratio is -8.43. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0I0X.L's ROE of -1.18%. Regarding short-term risk, AVCT.L is more volatile compared to 0I0X.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0I0X.L's competition here
AVCT.L vs FARN.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, FARN.L has a market cap of 215.5M. Regarding current trading prices, AVCT.L is priced at £47.00, while FARN.L trades at £192.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas FARN.L's P/E ratio is -7.70. In terms of profitability, AVCT.L's ROE is -0.90%, compared to FARN.L's ROE of +0.01%. Regarding short-term risk, AVCT.L is more volatile compared to FARN.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check FARN.L's competition here
AVCT.L vs ARIX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ARIX.L has a market cap of 183.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while ARIX.L trades at £142.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ARIX.L's P/E ratio is 12.91. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ARIX.L's ROE of -0.11%. Regarding short-term risk, AVCT.L is more volatile compared to ARIX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check ARIX.L's competition here
AVCT.L vs 4BB.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 4BB.L has a market cap of 150.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while 4BB.L trades at £970.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 4BB.L's P/E ratio is -10.32. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 4BB.L's ROE of -1.17%. Regarding short-term risk, AVCT.L is more volatile compared to 4BB.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 4BB.L's competition here
AVCT.L vs BVXP.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, BVXP.L has a market cap of 139.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while BVXP.L trades at £2,665.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas BVXP.L's P/E ratio is 18.01. In terms of profitability, AVCT.L's ROE is -0.90%, compared to BVXP.L's ROE of +0.67%. Regarding short-term risk, AVCT.L is more volatile compared to BVXP.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check BVXP.L's competition here
AVCT.L vs SCLP.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, SCLP.L has a market cap of 106.4M. Regarding current trading prices, AVCT.L is priced at £47.00, while SCLP.L trades at £10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas SCLP.L's P/E ratio is -5.12. In terms of profitability, AVCT.L's ROE is -0.90%, compared to SCLP.L's ROE of +1.66%. Regarding short-term risk, AVCT.L is less volatile compared to SCLP.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check SCLP.L's competition here
AVCT.L vs HVO.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, HVO.L has a market cap of 68.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while HVO.L trades at £10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas HVO.L's P/E ratio is 5.00. In terms of profitability, AVCT.L's ROE is -0.90%, compared to HVO.L's ROE of +0.42%. Regarding short-term risk, AVCT.L is more volatile compared to HVO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check HVO.L's competition here
AVCT.L vs REDX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, REDX.L has a market cap of 58.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while REDX.L trades at £15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas REDX.L's P/E ratio is -1.50. In terms of profitability, AVCT.L's ROE is -0.90%, compared to REDX.L's ROE of -1.81%. Regarding short-term risk, AVCT.L is more volatile compared to REDX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check REDX.L's competition here
AVCT.L vs OBI.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, OBI.L has a market cap of 57.8M. Regarding current trading prices, AVCT.L is priced at £47.00, while OBI.L trades at £13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas OBI.L's P/E ratio is -3.25. In terms of profitability, AVCT.L's ROE is -0.90%, compared to OBI.L's ROE of -6.84%. Regarding short-term risk, AVCT.L is more volatile compared to OBI.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check OBI.L's competition here
AVCT.L vs ETX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ETX.L has a market cap of 56.4M. Regarding current trading prices, AVCT.L is priced at £47.00, while ETX.L trades at £9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ETX.L's P/E ratio is -4.50. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ETX.L's ROE of -0.41%. Regarding short-term risk, AVCT.L is more volatile compared to ETX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check ETX.L's competition here
AVCT.L vs SBTX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, SBTX.L has a market cap of 43.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while SBTX.L trades at £16.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas SBTX.L's P/E ratio is -16.75. In terms of profitability, AVCT.L's ROE is -0.90%, compared to SBTX.L's ROE of -0.69%. Regarding short-term risk, AVCT.L is more volatile compared to SBTX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check SBTX.L's competition here
AVCT.L vs FUM.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, FUM.L has a market cap of 38M. Regarding current trading prices, AVCT.L is priced at £47.00, while FUM.L trades at £12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas FUM.L's P/E ratio is -12.50. In terms of profitability, AVCT.L's ROE is -0.90%, compared to FUM.L's ROE of +0.15%. Regarding short-term risk, AVCT.L is more volatile compared to FUM.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check FUM.L's competition here
AVCT.L vs MTPH.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, MTPH.L has a market cap of 31.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while MTPH.L trades at £18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas MTPH.L's P/E ratio is -0.22. In terms of profitability, AVCT.L's ROE is -0.90%, compared to MTPH.L's ROE of -1.12%. Regarding short-term risk, AVCT.L is more volatile compared to MTPH.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check MTPH.L's competition here
AVCT.L vs 0RA2.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0RA2.L has a market cap of 30.9M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0RA2.L trades at £1.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0RA2.L's P/E ratio is -1.93. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0RA2.L's ROE of +0.32%. Regarding short-term risk, AVCT.L is less volatile compared to 0RA2.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check 0RA2.L's competition here
AVCT.L vs C4XD.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, C4XD.L has a market cap of 30.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while C4XD.L trades at £12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas C4XD.L's P/E ratio is 3.00. In terms of profitability, AVCT.L's ROE is -0.90%, compared to C4XD.L's ROE of -1.21%. Regarding short-term risk, AVCT.L is more volatile compared to C4XD.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check C4XD.L's competition here
AVCT.L vs TRX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, TRX.L has a market cap of 24.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while TRX.L trades at £34.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas TRX.L's P/E ratio is -34.00. In terms of profitability, AVCT.L's ROE is -0.90%, compared to TRX.L's ROE of -0.02%. Regarding short-term risk, AVCT.L is more volatile compared to TRX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check TRX.L's competition here
AVCT.L vs OKYO.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, OKYO.L has a market cap of 23.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while OKYO.L trades at £1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas OKYO.L's P/E ratio is -1.40. In terms of profitability, AVCT.L's ROE is -0.90%, compared to OKYO.L's ROE of -1.36%. Regarding short-term risk, AVCT.L is more volatile compared to OKYO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check OKYO.L's competition here
AVCT.L vs SAR.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, SAR.L has a market cap of 23M. Regarding current trading prices, AVCT.L is priced at £47.00, while SAR.L trades at £17.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas SAR.L's P/E ratio is -5.67. In terms of profitability, AVCT.L's ROE is -0.90%, compared to SAR.L's ROE of -0.64%. Regarding short-term risk, AVCT.L is more volatile compared to SAR.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check SAR.L's competition here
AVCT.L vs AREC.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, AREC.L has a market cap of 21.5M. Regarding current trading prices, AVCT.L is priced at £47.00, while AREC.L trades at £57.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas AREC.L's P/E ratio is -1.84. In terms of profitability, AVCT.L's ROE is -0.90%, compared to AREC.L's ROE of -1.96%. Regarding short-term risk, AVCT.L is more volatile compared to AREC.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check AREC.L's competition here
AVCT.L vs 0V43.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0V43.L has a market cap of 20.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0V43.L trades at £0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0V43.L's P/E ratio is -1.37. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0V43.L's ROE of -1.25%. Regarding short-term risk, AVCT.L is more volatile compared to 0V43.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0V43.L's competition here
AVCT.L vs POLB.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, POLB.L has a market cap of 18.8M. Regarding current trading prices, AVCT.L is priced at £47.00, while POLB.L trades at £2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas POLB.L's P/E ratio is -2.70. In terms of profitability, AVCT.L's ROE is -0.90%, compared to POLB.L's ROE of -0.33%. Regarding short-term risk, AVCT.L is more volatile compared to POLB.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check POLB.L's competition here
AVCT.L vs 0HUZ.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0HUZ.L has a market cap of 14.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0HUZ.L trades at £0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0HUZ.L's P/E ratio is -0.22. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0HUZ.L's ROE of -3.02%. Regarding short-term risk, AVCT.L is less volatile compared to 0HUZ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check 0HUZ.L's competition here
AVCT.L vs NSCI.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, NSCI.L has a market cap of 12.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while NSCI.L trades at £53.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas NSCI.L's P/E ratio is -4.83. In terms of profitability, AVCT.L's ROE is -0.90%, compared to NSCI.L's ROE of N/A. Regarding short-term risk, AVCT.L is more volatile compared to NSCI.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check NSCI.L's competition here
AVCT.L vs FAB.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, FAB.L has a market cap of 12.5M. Regarding current trading prices, AVCT.L is priced at £47.00, while FAB.L trades at £11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas FAB.L's P/E ratio is -5.50. In terms of profitability, AVCT.L's ROE is -0.90%, compared to FAB.L's ROE of -1.14%. Regarding short-term risk, AVCT.L is less volatile compared to FAB.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check FAB.L's competition here
AVCT.L vs OPTI.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, OPTI.L has a market cap of 11.6M. Regarding current trading prices, AVCT.L is priced at £47.00, while OPTI.L trades at £11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas OPTI.L's P/E ratio is -5.62. In terms of profitability, AVCT.L's ROE is -0.90%, compared to OPTI.L's ROE of -0.23%. Regarding short-term risk, AVCT.L is more volatile compared to OPTI.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check OPTI.L's competition here
AVCT.L vs SNG.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, SNG.L has a market cap of 11.6M. Regarding current trading prices, AVCT.L is priced at £47.00, while SNG.L trades at £0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas SNG.L's P/E ratio is -0.47. In terms of profitability, AVCT.L's ROE is -0.90%, compared to SNG.L's ROE of -0.29%. Regarding short-term risk, AVCT.L is less volatile compared to SNG.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check SNG.L's competition here
AVCT.L vs IXI.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, IXI.L has a market cap of 11.4M. Regarding current trading prices, AVCT.L is priced at £47.00, while IXI.L trades at £12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas IXI.L's P/E ratio is -6.12. In terms of profitability, AVCT.L's ROE is -0.90%, compared to IXI.L's ROE of -0.21%. Regarding short-term risk, AVCT.L is more volatile compared to IXI.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check IXI.L's competition here
AVCT.L vs OBD.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, OBD.L has a market cap of 11.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while OBD.L trades at £0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas OBD.L's P/E ratio is -0.19. In terms of profitability, AVCT.L's ROE is -0.90%, compared to OBD.L's ROE of -3.87%. Regarding short-term risk, AVCT.L is more volatile compared to OBD.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check OBD.L's competition here
AVCT.L vs IMM.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, IMM.L has a market cap of 11.1M. Regarding current trading prices, AVCT.L is priced at £47.00, while IMM.L trades at £2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas IMM.L's P/E ratio is -2.08. In terms of profitability, AVCT.L's ROE is -0.90%, compared to IMM.L's ROE of -0.66%. Regarding short-term risk, AVCT.L is less volatile compared to IMM.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check IMM.L's competition here
AVCT.L vs APTA.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, APTA.L has a market cap of 9.6M. Regarding current trading prices, AVCT.L is priced at £47.00, while APTA.L trades at £0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas APTA.L's P/E ratio is -0.36. In terms of profitability, AVCT.L's ROE is -0.90%, compared to APTA.L's ROE of -1.31%. Regarding short-term risk, AVCT.L is less volatile compared to APTA.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check APTA.L's competition here
AVCT.L vs BVX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, BVX.L has a market cap of 8.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while BVX.L trades at £10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas BVX.L's P/E ratio is -2.50. In terms of profitability, AVCT.L's ROE is -0.90%, compared to BVX.L's ROE of -0.91%. Regarding short-term risk, AVCT.L is more volatile compared to BVX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check BVX.L's competition here
AVCT.L vs 0HTC.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0HTC.L has a market cap of 8.1M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0HTC.L trades at £5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0HTC.L's P/E ratio is -2.96. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0HTC.L's ROE of +499.47%. Regarding short-term risk, AVCT.L is more volatile compared to 0HTC.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0HTC.L's competition here
AVCT.L vs HEMO.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, HEMO.L has a market cap of 7.1M. Regarding current trading prices, AVCT.L is priced at £47.00, while HEMO.L trades at £154.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas HEMO.L's P/E ratio is -0.85. In terms of profitability, AVCT.L's ROE is -0.90%, compared to HEMO.L's ROE of -1.42%. Regarding short-term risk, AVCT.L is more volatile compared to HEMO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check HEMO.L's competition here
AVCT.L vs CIZ.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, CIZ.L has a market cap of 6.1M. Regarding current trading prices, AVCT.L is priced at £47.00, while CIZ.L trades at £1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas CIZ.L's P/E ratio is -1.55. In terms of profitability, AVCT.L's ROE is -0.90%, compared to CIZ.L's ROE of -0.00%. Regarding short-term risk, AVCT.L is less volatile compared to CIZ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check CIZ.L's competition here
AVCT.L vs TCF.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, TCF.L has a market cap of 5.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while TCF.L trades at £0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas TCF.L's P/E ratio is -0.24. In terms of profitability, AVCT.L's ROE is -0.90%, compared to TCF.L's ROE of -1.17%. Regarding short-term risk, AVCT.L is more volatile compared to TCF.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check TCF.L's competition here
AVCT.L vs CRTX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, CRTX.L has a market cap of 4.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while CRTX.L trades at £10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas CRTX.L's P/E ratio is -5.37. In terms of profitability, AVCT.L's ROE is -0.90%, compared to CRTX.L's ROE of -0.22%. Regarding short-term risk, AVCT.L is more volatile compared to CRTX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check CRTX.L's competition here
AVCT.L vs 0R02.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0R02.L has a market cap of 3.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0R02.L trades at £0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0R02.L's P/E ratio is -0.20. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0R02.L's ROE of -0.47%. Regarding short-term risk, AVCT.L is more volatile compared to 0R02.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0R02.L's competition here
AVCT.L vs EVG.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, EVG.L has a market cap of 3.5M. Regarding current trading prices, AVCT.L is priced at £47.00, while EVG.L trades at £0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas EVG.L's P/E ratio is -0.82. In terms of profitability, AVCT.L's ROE is -0.90%, compared to EVG.L's ROE of -0.82%. Regarding short-term risk, AVCT.L is more volatile compared to EVG.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check EVG.L's competition here
AVCT.L vs GENF.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, GENF.L has a market cap of 3.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while GENF.L trades at £0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas GENF.L's P/E ratio is -0.70. In terms of profitability, AVCT.L's ROE is -0.90%, compared to GENF.L's ROE of -1.05%. Regarding short-term risk, AVCT.L is less volatile compared to GENF.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check GENF.L's competition here
AVCT.L vs DEST.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, DEST.L has a market cap of 2.9M. Regarding current trading prices, AVCT.L is priced at £47.00, while DEST.L trades at £3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas DEST.L's P/E ratio is -0.50. In terms of profitability, AVCT.L's ROE is -0.90%, compared to DEST.L's ROE of -0.67%. Regarding short-term risk, AVCT.L is more volatile compared to DEST.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check DEST.L's competition here
AVCT.L vs ROQ.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ROQ.L has a market cap of 2.7M. Regarding current trading prices, AVCT.L is priced at £47.00, while ROQ.L trades at £1.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ROQ.L's P/E ratio is -1.70. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ROQ.L's ROE of -0.30%. Regarding short-term risk, AVCT.L is less volatile compared to ROQ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check ROQ.L's competition here
AVCT.L vs VAL.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, VAL.L has a market cap of 2.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while VAL.L trades at £0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas VAL.L's P/E ratio is -0.60. In terms of profitability, AVCT.L's ROE is -0.90%, compared to VAL.L's ROE of -0.47%. Regarding short-term risk, AVCT.L is more volatile compared to VAL.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check VAL.L's competition here
AVCT.L vs RENE.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, RENE.L has a market cap of 1.9M. Regarding current trading prices, AVCT.L is priced at £47.00, while RENE.L trades at £3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas RENE.L's P/E ratio is -0.38. In terms of profitability, AVCT.L's ROE is -0.90%, compared to RENE.L's ROE of -0.72%. Regarding short-term risk, AVCT.L is more volatile compared to RENE.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check RENE.L's competition here
AVCT.L vs 0QNV.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0QNV.L has a market cap of 1.6M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0QNV.L trades at £0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0QNV.L's P/E ratio is -0.11. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0QNV.L's ROE of +0.83%. Regarding short-term risk, AVCT.L is more volatile compared to 0QNV.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0QNV.L's competition here
AVCT.L vs 0R55.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0R55.L has a market cap of 1.6M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0R55.L trades at £0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0R55.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0R55.L's ROE of +0.34%. Regarding short-term risk, AVCT.L is more volatile compared to 0R55.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0R55.L's competition here
AVCT.L vs NFX.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, NFX.L has a market cap of 1.5M. Regarding current trading prices, AVCT.L is priced at £47.00, while NFX.L trades at £0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas NFX.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.90%, compared to NFX.L's ROE of -0.00%. Regarding short-term risk, AVCT.L is more volatile compared to NFX.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check NFX.L's competition here
AVCT.L vs PYC.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, PYC.L has a market cap of 1.4M. Regarding current trading prices, AVCT.L is priced at £47.00, while PYC.L trades at £0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas PYC.L's P/E ratio is -0.46. In terms of profitability, AVCT.L's ROE is -0.90%, compared to PYC.L's ROE of -1.81%. Regarding short-term risk, AVCT.L is more volatile compared to PYC.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check PYC.L's competition here
AVCT.L vs ONC.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ONC.L has a market cap of 1.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while ONC.L trades at £1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ONC.L's P/E ratio is -0.23. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ONC.L's ROE of +1.97%. Regarding short-term risk, AVCT.L is less volatile compared to ONC.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check ONC.L's competition here
AVCT.L vs OCTP.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, OCTP.L has a market cap of 1.3M. Regarding current trading prices, AVCT.L is priced at £47.00, while OCTP.L trades at £0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas OCTP.L's P/E ratio is -0.11. In terms of profitability, AVCT.L's ROE is -0.90%, compared to OCTP.L's ROE of -0.87%. Regarding short-term risk, AVCT.L is more volatile compared to OCTP.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check OCTP.L's competition here
AVCT.L vs 0QGJ.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0QGJ.L has a market cap of 1.2M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0QGJ.L trades at £0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0QGJ.L's P/E ratio is -0.22. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0QGJ.L's ROE of -0.78%. Regarding short-term risk, AVCT.L is less volatile compared to 0QGJ.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check 0QGJ.L's competition here
AVCT.L vs 0QSS.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0QSS.L has a market cap of 1M. Regarding current trading prices, AVCT.L is priced at £47.00, while 0QSS.L trades at £0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0QSS.L's P/E ratio is -0.06. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0QSS.L's ROE of -0.73%. Regarding short-term risk, AVCT.L is less volatile compared to 0QSS.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check 0QSS.L's competition here
AVCT.L vs OVB.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, OVB.L has a market cap of 938K. Regarding current trading prices, AVCT.L is priced at £47.00, while OVB.L trades at £1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas OVB.L's P/E ratio is -0.29. In terms of profitability, AVCT.L's ROE is -0.90%, compared to OVB.L's ROE of -0.52%. Regarding short-term risk, AVCT.L is more volatile compared to OVB.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check OVB.L's competition here
AVCT.L vs 0RGO.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, 0RGO.L has a market cap of 78.7K. Regarding current trading prices, AVCT.L is priced at £47.00, while 0RGO.L trades at £0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas 0RGO.L's P/E ratio is 0.10. In terms of profitability, AVCT.L's ROE is -0.90%, compared to 0RGO.L's ROE of -0.11%. Regarding short-term risk, AVCT.L is more volatile compared to 0RGO.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check 0RGO.L's competition here
AVCT.L vs SLN.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, SLN.L has a market cap of 0. Regarding current trading prices, AVCT.L is priced at £47.00, while SLN.L trades at £535.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas SLN.L's P/E ratio is -0.11. In terms of profitability, AVCT.L's ROE is -0.90%, compared to SLN.L's ROE of -2.17%. Regarding short-term risk, AVCT.L is more volatile compared to SLN.L. This indicates potentially higher risk in terms of short-term price fluctuations for AVCT.L.Check SLN.L's competition here
AVCT.L vs TILS.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, TILS.L has a market cap of 0. Regarding current trading prices, AVCT.L is priced at £47.00, while TILS.L trades at £58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas TILS.L's P/E ratio is -0.11. In terms of profitability, AVCT.L's ROE is -0.90%, compared to TILS.L's ROE of -1.26%. Regarding short-term risk, AVCT.L is less volatile compared to TILS.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check TILS.L's competition here
AVCT.L vs ABC.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ABC.L has a market cap of 0. Regarding current trading prices, AVCT.L is priced at £47.00, while ABC.L trades at £1,226.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ABC.L's P/E ratio is 2.04. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ABC.L's ROE of +0.01%. Regarding short-term risk, Volatility data is not available for a full comparison. AVCT.L has daily volatility of 10.94 and ABC.L has daily volatility of N/A.Check ABC.L's competition here
AVCT.L vs ORPH.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, ORPH.L has a market cap of 0. Regarding current trading prices, AVCT.L is priced at £47.00, while ORPH.L trades at £10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas ORPH.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.90%, compared to ORPH.L's ROE of -0.00%. Regarding short-term risk, Volatility data is not available for a full comparison. AVCT.L has daily volatility of 10.94 and ORPH.L has daily volatility of N/A.Check ORPH.L's competition here
AVCT.L vs RMS.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, RMS.L has a market cap of 0. Regarding current trading prices, AVCT.L is priced at £47.00, while RMS.L trades at £0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas RMS.L's P/E ratio is -0.04. In terms of profitability, AVCT.L's ROE is -0.90%, compared to RMS.L's ROE of -0.44%. Regarding short-term risk, AVCT.L is less volatile compared to RMS.L. This indicates potentially lower risk in terms of short-term price fluctuations for AVCT.L.Check RMS.L's competition here
AVCT.L vs DDDD.L Comparison August 2025
AVCT.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AVCT.L stands at 188.7M. In comparison, DDDD.L has a market cap of 0. Regarding current trading prices, AVCT.L is priced at £47.00, while DDDD.L trades at £16.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AVCT.L currently has a P/E ratio of -5.22, whereas DDDD.L's P/E ratio is N/A. In terms of profitability, AVCT.L's ROE is -0.90%, compared to DDDD.L's ROE of -1.06%. Regarding short-term risk, Volatility data is not available for a full comparison. AVCT.L has daily volatility of 10.94 and DDDD.L has daily volatility of N/A.Check DDDD.L's competition here